Predictors of Early Stroke or Death in Patients Undergoing Transcatheter Aortic Valve Implantation

Copyright © 2021 Elsevier Inc. All rights reserved..

BACKGROUND/OBJECTIVE: While postoperative stroke is a known complication of Transcatheter Aortic Valve Implantation (TAVI), predictors of early stroke occurrence have not been specifically reviewed. The objective of this study was to estimate the predictors and incidence of stroke during the first 30 days post-TAVI.

METHODS: A cohort of 506 consecutive patients having undergone TAVI between January 2017 and June 2019 was extracted from a prospective database. Preoperative, intraoperative and postoperative characteristics were analyzed by univariate analysis followed by logistic regression to find predictors of the occurrence of stroke or death within the first 30 days after the procedure.

RESULTS: Incidence of stroke within 30 days post-TAVI was 4.9%, [CI 95% 3.3-7.2], i.e., 25 strokes. Four out of the 25 patients (16%) with a stroke died within 30 days post-TAVI. After logistic regression analysis, the predictors of early stroke related to TAVI were: CHA2Ds2VASc score ≥ 5 (odds ratio [OR] 2.62; 95% CI: 1.06-6.49; p = .037), supra-aortic access vs. femoral access (OR: 9.00, 95%CI: 2.95-27.44; p = .001) and introduction post-TAVI of a single vs. two or three antithrombotic agents (OR: 5.13; CI 95%: 1.99 to 13.19; p = .001). Over the 30-day period, bleeding occurred in 28 patients (5.5%), in 25 of whom, it was associated with femoral or iliac artery access injury. Anti-thrombotic regimen was not associated with bleeding; two patients out of 48 (4.1%) bled with a single anti-thrombotic regimen vs. 26 patients out of 458 (5.6%) with a dual or triple anti-thrombotic regimen (p = 0.94). The overall 30-day mortality rate was 3.9%, [95% CI 2.5-6.0]. Patients with a single post-TAVI antithrombotic agent (OR: 44.07 [CI 95% 13.45-144.39]; p < .0001) and patients with previous coronary artery bypass surgery or coronary artery stenting (OR: 6.16, [CI 95% 1.99-21.29]; p = .002) were at significantly higher risk of death within the 30-day period.

CONCLUSION: In this large-scale single-center retrospective study, a single post-TAVI antithrombotic regimen independently predicted occurrence of early stroke or death. Dual or triple antithrombotic regimen was not associated with a higher risk of bleeding and should be considered as an option in patients undergoing TAVI.

Medienart:

E-Artikel

Erscheinungsjahr:

2021

Erschienen:

2021

Enthalten in:

Zur Gesamtaufnahme - volume:30

Enthalten in:

Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association - 30(2021), 8 vom: 30. Aug., Seite 105912

Sprache:

Englisch

Beteiligte Personen:

Ricco, Jean-Baptiste [VerfasserIn]
Castagnet, Hélène [VerfasserIn]
Christiaens, Luc [VerfasserIn]
Palazzo, Paola [VerfasserIn]
Lamy, Matthias [VerfasserIn]
Mergy, Jean [VerfasserIn]
Corbi, Pierre [VerfasserIn]
Neau, Jean-Philippe [VerfasserIn]

Links:

Volltext

Themen:

Anticoagulant treatment
Aortic valve stenosis
Fibrinolytic Agents
Heart valve prosthesis implantation
Journal Article
Risk factors
Stroke
Transcatheter Aortic Valve Implantation

Anmerkungen:

Date Completed 26.07.2021

Date Revised 26.07.2021

published: Print-Electronic

Citation Status MEDLINE

doi:

10.1016/j.jstrokecerebrovasdis.2021.105912

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

NLM326777725